General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | -0.89 | -0.79 | 0.1 | 11.24% |
2024-03-27 | 2023-12 | -1.23 | -1.19 | 0.04 | 3.25% |
2023-11-14 | 2023-09 | -1.12 | -1.35 | -0.23 | -20.54% |
2023-08-08 | 2023-06 | -1.11 | -1.3 | -0.19 | -17.12% |
2023-05-10 | 2023-03 | -1.12 | -0.85 | 0.27 | 24.11% |
2023-03-02 | 2022-12 | -1.27 | -1.28 | -0.01 | -0.79% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-02 | Piper Sandler | Upgrade | Overweight | Overweight |
2023-08-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-02 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-02 | Oppenheimer | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-20 | AKKARAJU SRINIVAS | Director | 0.00 | Purchase |
2023-09-14 | ALLES MARK J | Director | 3.67K | Conversion of Exercise of derivative security |
2024-03-27 | CHEE CONLEY | Chief Executive Officer | 22.50K | Conversion of Exercise of derivative security |
2024-03-27 | HAAS JASON | Chief Financial Officer | 24.55K | Conversion of Exercise of derivative security |
2023-07-16 | OLSON ERIC R. | Officer | 6.66K | Sale |
2024-03-26 | QUIRK GERALD E. | Officer | 39.76K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Bain Capital Life Sciences Investors, LLC | 2.12M | 6.69M | 10.26% |
2023-06-29 | Artal Group S.A. | 1.48M | 4.65M | 7.13% |
2023-06-29 | Avidity Partners Management, LP | 1.46M | 4.61M | 7.07% |
2023-06-29 | Flagship Pioneering Inc. | 993.85K | 3.13M | 4.80% |
2023-06-29 | Samsara BioCapital, LLC | 881.45K | 2.78M | 4.26% |
2023-06-29 | Chi Advisors Llc | 767.45K | 2.42M | 3.71% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 321.95K | 1.01M | 1.55% |
2023-06-29 | Vanguard Extended Market Index Fund | 140.12K | 441.37K | 0.68% |
2023-08-30 | iShares Micro Cap ETF | 45.50K | 177.45K | 0.22% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 38.67K | 121.81K | 0.19% |
2023-05-30 | Fidelity Extended Market Index Fund | 37.16K | 143.07K | 0.18% |
2023-06-29 | Price (T.Rowe) Extended Equity Market Index Fund | 22.55K | 71.03K | 0.11% |
Split | Date |
---|---|
1 : 10 | 2022-09-19 |
Visionary Education Technology Holdings Group Inc. Will Be Changing Its Ticker Symbol From "VEDU" To "GV". Effective When The Market Opens On Monday, October 9, 2023
Benzinga
·
10/02 16:01
1min
Veru Inc(VERU.US)
0.780
+2.23%
Visionary Education Technology(VEDU.US)
0.188
+12.68%
Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ:VEDU), a private education provider located in Canada, with subsidiaries in Canada and market partners in China, today announced that it will be changing its ticker symbol from "VEDU" to "GV". Effective when the market opens on Monday, October 9, 2023, its common shares will trade on NASDAQ under the new ticker symbol "GV".
No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's common shares will continue to be listed on NASDAQ and its CUSIP number will remain unchanged.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investm
Very common for the market to initially react negative to any significant change. The new CEO is a huge win for Syros. It was time for a new vision and direction. Best to make the move prior to a positive printout. Rumors of an acquisition make sense.
Management needs to step up. We’ve allowed them to collect exuberant salaries and all they’ve done is ignored the original shareholders. Is it time to initiate a shareholder advocacy group? Very frustrated by their lack of caring. They claim to care about patients while lining their pockets. Maybe it’s time to engage a counter offensive. Or management should work to get the company acquired or engage new leadership that knows how to advance a company and it’s value.